ELOX stock Statistics — Eloxx Pharmaceuticals, Inc. filings, insiders & smart money

Price and daily changeSign in

Earnings10 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-07 · filed common shares: 4.03M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 10.58%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 0.71%
Short ratioDays to cover, as published by FINRA: 1.00
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 40.10%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 58.50%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -115.02%
Return on assets: —

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

8.42

EPS (fwd)

Cash & equivalentsas of Jun 26: $61.96M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Dec 25: $1.00M
Debt / equityas of Dec 25: -8.40%
Current ratioas of Jun 26: 3.74
Quick ratio: —
Operating cash flowTTM to Jun 26: -$16.02M
Free cash flowUnadjusted FCF = CFO − capex · FY Dec 25: -$6.32M
TTM revenue / diluted share: —